Clinical-stage biotech developing nanobody therapeutics for infectious diseases
| Date | Round | Amount |
|---|---|---|
| Jan 2023 | Debt ExeVir Bio raised EUR25M in venture debt from the European Investment Bank for its COVID-19 antibody therapeutic. | $25M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.